Gastroenterology

Gastroenterology

Volume 119, Issue 3, September 2000, Pages 724-733
Gastroenterology

Alimentary Tract
Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis,☆☆

https://doi.org/10.1053/gast.2000.16500Get rights and content

Abstract

Background & Aims: Most experimental models for inflammatory bowel disease in mice are associated with production of interferon (IFN)-γ and other proinflammatory cytokines. We hypothesized that T-helper 2 (Th2)-type cells could also contribute to the colitis and cause inflammation different than that mediated by Th1-type cells. Methods: Trinitrobenzene sulfonic acid (TNBS)-induced colitis in C57BL/6 background mice genetically deficient in interleukin (IL)-12 p40 (IL-12−/−), IFN-γ (IFN-γ−/−), or IL-4 (IL-4−/−) was examined in comparison with control mice (C57BL/6+/+). Results: C57BL/6+/+, IFN-γ−/−, and IL-12−/− mice developed patterns of colitis characterized by distortion of crypts, loss of goblet cells, and mononuclear cell infiltration with fibrosis of the mucosal layer. IL-4−/− mice had greater mortality than other groups because of penetrating ulcers; however, survivors developed milder lesions that were limited to focal acute ulceration. Colonic CD4+ T cells from normal, IFN-γ−/−, or IL-12−/− mice produced both IL-4 and IL-5. Conclusions: In TNBS colitis, Th1-like cytokine responses induce fatal, acute, transmural, and focal types of lesions, whereas Th2-like cytokine responses play a significant role in the diffuse atrophic changes in crypts and the mucosal layer that occur in the late stages of this disease.

GASTROENTEROLOGY 2000;119:724-733

Section snippets

Mice

Normal, IFN-γ gene–disrupted (IFN-γ−/−), IL-4 gene–disrupted (IL-4−/−), and IL-12 p40 gene–disrupted (IL-12−/−) mice, all of C57BL/6 background, and IL-12 p40 gene–disrupted (IL-12−/−) and IL-4−/− BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME). The mice were kept in microisolator cages in animal facilities at the Immunobiology Vaccine Center University of Alabama at Birmingham.

Induction of colitis

Mice were given a solution of TNBS (Research Organics, Cleveland, OH) dissolved in a mixture

Sensitivity of cytokine-deficient mice to TNBS colitis

For induction of TNBS colitis in cytokine gene–disrupted and control C57BL/6 (C57BL/6+/+) mice, we initially optimized the dose of hapten required to induce colitis. Both mortality and colitis in C57BL/6+/+ mice were dose dependent, and 40 μg/g body wt induced colitis with minimum death (Table 1).This dose was subsequently used in all experiments. Both IL-12−/− and C57BL/6+/+ mice showed similar degrees of survival after TNBS enema treatment, but IFN-γ−/− mice tended to be more resistant,

Acknowledgements

The authors thank Dr. Giorgio Trinchieri for providing hybridomas for anti–IL-12 monoclonal antibodies; Dr. Ed Leiter for discussions of this work and manuscript; Drs. Prosper N. Boyaka and John L. VanCott for lending their expertise with IL-12−/− and IFN-γ−/− mice; Drs. Casey Weaver and Audrey J. Lazenby for important discussions on histopathology of lesions; Dr. Raymond J. Jackson for help with the TGF-β assay; Annette M. Pitts for preparation of the tissues for histology; and Dr. Kim McGhee

References (25)

  • U Rudolph et al.

    Ulcerative colitis and adenocarcinoma of the colon in Gαi2-deficient mice

    Nat Genet

    (1995)
  • PJ Morrissey et al.

    CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells

    J Exp Med

    (1993)
  • Cited by (0)

    Address requests for reprints to: Taeko Dohi, M.D., Department of Gastroenterology, Research Institute, International Medical Center of Japan, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. e-mail: [email protected]; fax: (81) 3-3202-7364.

    ☆☆

    Supported by U.S. Public Health Service National Institutes of Health grants DK 44240, AI 18958, DE 09837, DE 12242, AI 43197, and AI 35932; and by a grant and contracts from Ministry of Education, Science, Sports and Cultures, the Ministry of Health and Welfare, and Organization for Pharmaceutical Safety and Research of Japan.

    View full text